Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F0MA6
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,826
Award facts
- Contract value 100% obligated
- $13,826.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 13, 2026, the Defense Logistics Agency awarded a $13,826.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 300 mg/2 mL DUPIXENT pens. This non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of January 14, 2026. AmerisourceBergen Drug Corp operates as a subsidiary of parent company Cencora, Inc., which conducts business as AmerisourceBergen and serves as a critical pharmaceutical distributor for federal military and healthcare systems.
As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications and medical products across multiple therapeutic domains to support military healthcare programs globally. DUPIXENT (dupilumab) is a biologic medication commonly prescribed for treating moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe asthma, making this delivery order part of the company's ongoing role in supporting the Defense Health Agency and military treatment facilities. The firm fixed-price structure and rapid completion timeline reflect the delivery-order nature of this procurement under the existing DLA Troop Support Medical vehicle, which enables flexible and efficient fulfillment of pharmaceutical needs across the defense medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F0MA6?
SPE2DR26F0MA6 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26F0MA6 worth?
The government has obligated $13,826 on SPE2DR26F0MA6.
Is contract SPE2DR26F0MA6 an order under another contract?
Yes. SPE2DR26F0MA6 is a delivery order under SPE2DR25D3007, an indefinite delivery contract.
Was contract SPE2DR26F0MA6 competed?
The extent of competition for SPE2DR26F0MA6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award